Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 858 of 5804
-
Gentler transplant shows promise for kids with blood diseases
Disease control CompletedThis Phase II pilot study evaluates the safety and effectiveness of reduced-intensity conditioning (RIC) regimens prior to allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric and young adult patients with non-malignant disorders, including immunodeficiencies an…
Phase: PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for recurrent ovarian cancer: drug combo and surgery may extend life
Disease control OngoingThis randomized phase III trial studies carboplatin, paclitaxel and gemcitabine hydrochloride when given together with or without bevacizumab after surgery to see how well it works in treating patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer that ha…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Robotic scalpel takes on head and neck cancer
Disease control Recruiting nowThis pilot clinical trial studies transoral robotic surgery (TORS) in treating patients with benign or malignant tumors of the head and neck. TORS is a less invasive type of surgery for head and neck cancer and may have fewer side effects and improve recovery
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Major trial pits two drug cocktails against Hard-to-Treat cancers
Disease control OngoingThis randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b to see how well it works compared to octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors that have spread to other places in the body (metastatic…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a blood flow blocker stop breast cancer return?
Disease control OngoingThis randomized phase III trial studies doxorubicin hydrochloride, cyclophosphamide, and paclitaxel to see how well they work with or without bevacizumab in treating patients with cancer that has spread to the lymph nodes (lymph node-positive) or cancer that has not spread to the…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for toddlers with brain cancer: stem cell rescue trial
Disease control CompletedThis randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work in treating young patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma when given before additional inte…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can stem cells tame Crohn's? new trial tests Long-Term relief
Disease control CompletedProtocol 610 is enrolling subjects who successfully achieved clinical benefit (reduction in Crohn's Disease Activity Index (CDAI) of at least 100 points) in Protocol 603. Protocol 610 is evaluating the length of initial effect of PROCHYMAL® adult human mesenchymal stem cells and …
Phase: PHASE3 • Sponsor: Mesoblast, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could stem cells tame Crohn's? new trial tests infusion for remission
Disease control CompletedProtocol 603 is enrolling subjects with moderate-to-severe Crohn's disease who are intolerant to, or have previously failed therapy with, at least one steroid and at least one immunosuppressant and a biologic monoclonal anti-body to tumor necrosis factor alpha. The protocol inves…
Phase: PHASE3 • Sponsor: Mesoblast, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for advanced thyroid cancer: drug shows tumor-shrinking promise
Disease control CompletedDue to arguments showing that angiogenesis could be involved in progression of metastatic thyroid carcinoma and to objective response during previous studies with sunitinib (an angiogenic oncology drug also known as Sutent), this study, THYSU, is justified to evaluate the efficac…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Lymphoma trial tests which chemo combo works best for younger patients
Disease control CompletedThis Phase II study randomized R-ACVBP and R-CHOP as induction treatment in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI. The consolidation treatment is allocated according to the response to induction treatment as…
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 26, 2026 12:39 UTC
-
HIV vaccine race: which shot schedule wins?
⭐️ VACCINE ⭐️ CompletedThe purpose of the trial is to evaluate the effect upon immune system of two regimens of preventive HIV vaccination in healthy adult volunteers. Volunteers will be vaccinated by DNA-C and NYVAC-C vaccines, and the immune changes will be assessed, as well as safety of the vaccines…
Phase: PHASE1, PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:05 UTC
-
Liver-Directed chemo may shrink tumors enough for surgery in colorectal cancer
Disease control OngoingRATIONALE: Hepatic arterial infusion uses a catheter to carry tumor-killing substances directly into the liver. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving floxuridine a…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy shows promise for lymphoma in seniors
Disease control CompletedRATIONALE: Drugs used in chemotherapy, such as doxorubicin, vincristine, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Steroid therapy, such as prednisone, may be effective in treati…
Phase: PHASE2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Promising combo tackles Hard-to-Treat lymphoma
Disease control CompletedRATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the ce…
Phase: PHASE2 • Sponsor: NCIC Clinical Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for kids with wilms tumor: tailored treatment aims to stop relapse
Disease control CompletedThis phase III trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with newly diagnosed stage III or stage IV Wilms' tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, eith…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could a Two-Drug HIV combo protect babies without extra side effects?
Prevention CompletedIn the pre-partum phase the use of antiretroviral therapy for the mother during the last trimester of pregnancy is mandatory. The use of HAART during pregnancy, usually two nucleosides analogues and a protease inhibitor exposes the mother and the child to cumulate toxicities rela…
Phase: PHASE2, PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Prevention
Last updated Jun 27, 2026 12:04 UTC
-
ALS drug edaravone shows promise in slowing disease progression
Disease control CompletedThis is a long-term, double-blind, placebo-controlled study of MCI-186 to treat ALS. This study is the long-term extension of Study NCT00330681; Study NCT00330681 is a Phase 3, randomized, double-blind, placebo control, parallel assignment, 24-week study in the treatment of ALS. …
Phase: PHASE3 • Sponsor: Shionogi • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for kids with resistant neuroblastoma: targeted radiation plus chemo tested
Disease control CompletedRATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIGB), may carry radiation directly to tumor cells and not harm normal cells. Drugs used in chemotherapy, such as irinotecan and vincristine, work in different ways to stop the growth of tumor cells, eith…
Phase: PHASE1 • Sponsor: New Approaches to Neuroblastoma Therapy Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for myeloma patients with chromosome abnormalities?
Disease control OngoingWith this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with…
Phase: PHASE3 • Sponsor: University of Arkansas • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug cocktail shows promise for myeloma patients
Disease control OngoingThe purpose of this study is to determine the safety and efficacy of the bortezomib, lenalidomide and dexamethasone combination in patients with newly diagnosed multiple myeloma. We are looking for the highest dose of the combination that can be given safely and see how well it w…
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC